Nalmefene — Membership Pricing

Other medications in Addiction Medicine

• Nicotine Inhaler
• Lofexidine

About Nalmefene

Nalmefene is a prescription medication primarily used to help adults reduce their alcohol consumption, often as part of a broader treatment plan. For those seeking support in managing alcohol dependence, understanding treatment options and their costs is crucial. TheDrugClub is dedicated to making essential medications like nalmefene more accessible through significant savings for our members.

What is Nalmefene and What Does It Treat?

Nalmefene is a medication specifically approved for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high alcohol consumption level, without physical withdrawal symptoms, and who do not require immediate detoxification. It's not a cure for alcohol dependence, but rather a tool to help individuals cut back on their drinking. It's typically prescribed alongside ongoing psychosocial support, such as counseling or therapy, to provide a comprehensive approach to recovery. While primarily known for its role in alcohol dependence, nalmefene is an opioid antagonist, meaning it can block the effects of opioids. Historically, it has also been used in emergency settings to reverse opioid overdose, though naloxone is more commonly used for that purpose today.

How Does Nalmefene Work?

Nalmefene belongs to a class of drugs called opioid receptor antagonists. Its mechanism of action involves partially blocking the opioid receptors in the brain. When these receptors are activated, they contribute to the pleasurable sensations associated with drinking alcohol. By blocking these receptors, nalmefene helps to reduce the rewarding effects of alcohol, thereby decreasing the desire to drink and the amount consumed. It's often taken "as needed" – specifically, one to two hours before an anticipated drinking occasion – which allows for a flexible approach to managing alcohol intake. This targeted action helps individuals regain control over their drinking habits without necessarily requiring complete abstinence from alcohol from the outset of treatment.

Understanding Typical Costs and How TheDrugClub Can Help

The cost of nalmef

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Nalmefene is approved for (FDA label)

ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZURNAI is not a substitute for emergency medical care.

Source: Read the full FDA label on DailyMed. Label effective date: July 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Nalmefene (FDA label)

Injection: 1.5 mg nalmefene base/0.5 mL in a prefilled, single-dose auto-injector ( 3 ) Injection: 1.5 mg/0.5 mL nalmefene (base), clear, colorless to light yellow solution in a pre-filled, single-dose auto-injector. Each ZURNAI auto-injector delivers 1.5 mg nalmefene (base) injection (0.5 mL).

Source: FDA prescribing information (DailyMed). Set ID: a59a5847-9fe4-4341-a203-be0a5e6d3e36. SPL document ID: beb55b30-239d-4590-941f-669647d5c494. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nalmefene (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Recurrent Respiratory and Central Nervous System Depression [see Warnings and Precautions (5.1) ] Precipitation of Severe Opioid Withdrawal [see Warnings and Precautions (5.3) ] Most common adverse reactions (incidence > 5%) are feeling hot, nausea, headache, dizziness, chills, vomiting, allodynia, palpitations, tinnitus, ear discomfort, feeling abnormal, burning sensation, hot flush, and irritability. ( 6 ) To report Suspected Adverse Reactions, contact Knoa Pharma LLC at 1-888-726-7535 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Adult Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: a59a5847-9fe4-4341-a203-be0a5e6d3e36. SPL document ID: beb55b30-239d-4590-941f-669647d5c494. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nalmefene (FDA label)

ZURNAI is contraindicated in patients known to be hypersensitive to nalmefene hydrochloride or to any other ingredients in the product. Hypersensitivity to nalmefene hydrochloride or to any other ingredients in ZURNAI. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: a59a5847-9fe4-4341-a203-be0a5e6d3e36. SPL document ID: beb55b30-239d-4590-941f-669647d5c494. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Nalmefene (FDA label)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. ( 5.1 ) Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists : Reversal of respiratory depression by partial agonists or mixed agonist/antagonists such as buprenorphine and pentazocine, may be incomplete. Repeat doses may be required. ( 5.2 ) Precipitation of Severe Opioid Withdrawal : The use of ZURNAI in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal. ( 5.3 ) Risk of Cardiovascular (CV) Effects : Abrupt postoperative reversal of opioid depression may result in adverse CV effects.

Source: FDA prescribing information (DailyMed). Set ID: a59a5847-9fe4-4341-a203-be0a5e6d3e36. SPL document ID: beb55b30-239d-4590-941f-669647d5c494. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.